Occam Places David Mullarkey as CEO at Bluestar
Occam recently recruited David Mullarkey to Bluestar Genomics. He takes the helm of this rapidly evolving and highly innovative cancer detection company based on the scientific research of Stephen Quake of Stanford University. Dave comes to the role after having had great success as CEO of Omniome which was acquired by Pacific Biosciences and as President and COO of Ariosa Diagnostics sold to Roche. In addition to bringing deep content knowledge to Bluestar, he will provide strategic wisdom and operational discipline to the company’s imminent product launch and commercialization.
Recent Placements
Occam Global is a trusted executive search, consulting, and investment partner for leaders and investors shaping the future of life sciences, deep tech, and venture capital. Since 2012, we’ve helped build high-performing teams and advised visionary companies from stealth to public markets. Our success stems from exceptional access to rare talent, deep sector expertise, and a commitment to results guided by elevated ethics and enlightened aggression.